Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women

  • Taylor Segraves R
  • Croft H
  • Kavoussi R
 et al. 
  • 13


    Mendeley users who have this article in their library.
  • 85


    Citations of this article.


This article describes the results of the first report of bupropion sustained release (SR) in nondepressed females with hypoactive sexual desire disorder (HSDD). Eligible females entered a 4-week, single-blind, placebo baseline phase. Subjects, all of whom did not respond to placebo, continued in a single-blind active treatment phase where they received bupropion SR for up to 8 additional weeks. We assessed HSDD by using investigator ratings of sexual desire and sexual functioning. Of the 51 evaluable subjects who entered the active treatment phase, 29% responded to treatment with bupropion SR. Bupropion SR was generally well tolerated. Pending the results of further study, bupropion SR may offer a treatment option for women with HSDD.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • R. Taylor Segraves

  • Harry Croft

  • Richard Kavoussi

  • John A. Ascher

  • Sharyn R. Batey

  • Vicki J. Foster

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free